PDCD1 and melanoma: We therefore combined APR-246 with anti–PD-1 (RMP1-14) and anti–CTLA-4 (9D9) in B16-melanoma-bearing mice and found a significantly longer survival compared with dual ICB alone (P < 0.001) (Figure 1E and Supplemental Figure 1E).